Results 1 to 10 of about 16,507 (152)
Mineralocorticoid receptor antagonists reduce inflammatory signaling independent of myofiber mineralocorticoid receptor [PDF]
Endocrine and Metabolic ScienceChronic inflammation is a feature of Duchenne muscular dystrophy (DMD), a degenerative striated muscle disease. Mineralocorticoid receptor (MR) antagonists (MRAs) have demonstrated clinical benefit on later onset DMD cardiomyopathy, and preclinical ...
Jeovanna Lowe +5 more
doaj +5 more sources
Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease [PDF]
Pharmaceuticals, 2021 Diabetes mellitus is a global health issue and main cause of chronic kidney disease. Both diseases are also linked through high cardiovascular morbidity and mortality. Diabetic kidney disease (DKD) is present in up to 40% of diabetic patients; therefore,
Nina Vodošek Hojs +5 more
doaj +5 more sources
Cardiovascular-Kidney-Metabolic Effects: Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists [PDF]
Reviews in Cardiovascular MedicineCardiovascular (CV)-kidney-metabolic (CKM) syndrome is a complex disorder characterized by the co-occurrence of CV risk factors, including chronic kidney disease (CKD), hypertension, and metabolic dysfunction, which creates a vicious cycle where one ...
Biykem Bozkurt +2 more
doaj +2 more sources
Mineralocorticoid receptor antagonists for heart failure [PDF]
Expert Opinion on Pharmacotherapy, 2011 Although mineralocorticoid receptor (MR) antagonists are indicated in systolic heart failure, they are underprescribed in patients with appropriate indications for their prescription and often used in those in whom the evidence for probable benefit is scant.
Mark Richards
exaly +5 more sources
Heart failure: the role for mineralocorticoid receptor antagonists
Swiss Medical Weekly, 2014 Mineralocorticoid receptor antagonists (MRA’s) have been shown to be effective in patients with HFREF while their role in patients with HFPEF remains controversial. Despite a class one indication in both the ESC and AHA/ACC heart failure guidelines
Bertram Pitt
doaj +3 more sources
The Ascent of Mineralocorticoid Receptor Antagonists in Diabetic Nephropathy [PDF]
Current Clinical Pharmacology, 2019 Diabetic nephropathy is defined as a decline in the renal function and an increase in the amount of albuminuria (>300 mg/day). The interruption of the renin-angiotensin-aldosterone system (RAAS) by well-established therapies such as angiotensin-converting enzyme inhibitor, angiotensin receptor blockers, calcium channel blockers or diuretics has been
Melvin George, Luxitaa Goenka
exaly +3 more sources
Mineralocorticoid receptor antagonists in cardiovascular translational biology. [PDF]
Cardiovasc Endocrinol Metab, 2023 This review examines the role of mineralocorticoid receptor antagonists (MRAs) in cardiovascular biology and the molecular mechanisms involved in mineralocorticoid receptor antagonism. The data discussed suggest that MRAs can play an important role in decreasing the impact of inflammation and fibrosis on cardiorenal outcomes.
Chilton RJ, Silva-Cardoso J.
europepmc +3 more sources
Endogenous bufadienolides, mineralocorticoid receptor antagonists and fibrosis in chronic kidney disease [PDF]
Frontiers in PharmacologyEvery year millions die prematurely of complications related to chronic kidney disease (CKD). Main causes of death are connected with cardiovascular (CV) complications.
Mai Rosenberg, Alexei Y. Bagrov
doaj +2 more sources
Mineralocorticoid Receptor Antagonists [PDF]
International Cardiovascular Forum Journal, 2019 Two mineralocorticoid receptor antagonists, spironolactone and eplerenone, are currently approved by the FDA. Several non-steroid based ligands are in clinical trials for indications including heart failure, hypertension and diabetic kidney disease, and even more structurally distinct chemical series are reported in the literature with preclinical data
Anneli, Nordqvist, Kenneth L, Granberg
+5 more sources
Mineralocorticoid Receptor Antagonists in ESKD [PDF]
Clinical Journal of the American Society of Nephrology, 2020 There is an urgent need for interventions that reduce cardiovascular risks in patients with ESKD. Recently there has been considerable interest in whether blocking the effects of the mineralocorticoid aldosterone could be such an intervention.
Adhish, Agarwal, Alfred K, Cheung
openaire +2 more sources